What Are They For?
This medication class treats Group 1 pulmonary arterial hypertension (PAH) specifically — a disease of the small blood vessels in the lungs themselves. These medications are different from general heart medications: they act directly on the lung's blood vessels to relax and reopen them, reducing the workload on your heart's right side.
How They Help (In Plain Terms)
There are three main pathways these medications work through, often used in combination:
- Endothelin receptor antagonists (ERAs) block a hormone called endothelin that constricts blood vessels — blocking it allows the vessels to relax.
- PDE5 inhibitors and guanylate cyclase stimulators boost a natural vessel-relaxing signal (the nitric oxide pathway), similar in concept to how this pathway works elsewhere in the body.
- Prostacyclin pathway agents replace or mimic a natural substance that relaxes blood vessels and helps prevent clotting. These are available as pills, inhaled treatments, or — for more advanced disease — a continuous infusion delivered by a small pump, either under the skin or through a permanent IV line.
Common Examples
ERAs:
- Bosentan (Tracleer)
- Ambrisentan (Letairis)
- Macitentan (Opsumit)
PDE5 inhibitors / guanylate cyclase stimulators:
- Sildenafil (Revatio)
- Tadalafil (Adcirca)
- Riociguat (Adempas)
Prostacyclin pathway agents:
- Epoprostenol (Flolan, Veletri)
- Treprostinil (Remodulin, Orenitram, Tyvaso)
- Iloprost (Ventavis)
- Selexipag (Uptravi)
Common Side Effects to Know
- ERAs: fluid retention/swelling, and they require regular liver function monitoring
- PDE5 inhibitors/guanylate cyclase stimulators: headache, flushing, lightheadedness — related to the vessel-relaxing effect itself
- Prostacyclin pathway agents: headache, jaw pain, flushing, GI upset, and — for pump-delivered forms — site-related issues (infusion site pain or, for the inhaled/pump forms, technique-related side effects your team will train you on)
Practical Tips
- These medications are prescribed and titrated by a specialized pulmonary hypertension center, often starting at a low dose and increasing gradually as tolerated — that pattern is deliberate, not a sign something is wrong
- If you're on continuous pump-delivered prostacyclin therapy, never stop it abruptly — sudden discontinuation can cause a dangerous rebound in pulmonary pressures. Pump and catheter care for these infusion therapies deserves the same daily seriousness as Driveline Care & Dressing Changes — treat interruptions as a real emergency, not a missed dose to catch up on later
- Tell every provider you see about these medications, including dentists and surgeons, since some interact with other drugs or affect procedural planning
What Your Care Team Monitors
Your pulmonary hypertension specialist tracks your functional capacity (6-minute walk distance, sometimes CPET) and adjusts medications based on your response. Your cardiologist's role focuses on your right heart specifically — serial echocardiograms, periodic right heart catheterization, and sometimes a CardioMEMS sensor — to track how well the heart is tolerating treatment over time and to catch early signs that the treatment plan may need revisiting. (See Pulmonary Hypertension for more on how these two roles work together.)
Common Questions
Why am I seeing both a lung specialist and a cardiologist for the same condition?
Because PAH genuinely affects two connected systems — the lung blood vessels and the heart's right side — and each specialist manages a different, essential part of your care.
What happens if I miss a dose?
For most oral forms, ask your team for specific guidance; for continuous infusion therapy, a missed or interrupted dose can be serious — contact your team immediately rather than waiting.
Will I be on these long-term?
Generally yes — these treat an ongoing disease process rather than curing it, though your specific regimen is adjusted over time based on how you respond.
What's the difference between the pill, inhaled, and pump forms of these medications?
They're different delivery methods for reaching the prostacyclin pathway specifically, chosen based on how advanced your disease is and how well oral or inhaled options are controlling your symptoms — the pump form is generally reserved for more advanced disease needing continuous, higher-level dosing.